Crohn’s Disease Treatment Market, by Drug Type (Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jul 2022

Code : CMI1237

Pages :150

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Crohn’s Disease Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

The COVID-19 pandemic had a significant impact on the crohn’s disease treatment market, owing to the disease exacerbation due to the COVID-19 pandemic. For instance, according to an article published by the Frontiers Media S.A. in December 2021, a questionnaire survey on patients with Inflammatory Bowel Disease (IBD) from June 16 to August 21, 2020 during their regular follow-up at a hospital in Japan was carried out. According to the results, 241 patients with ulcerative colitis (UC) and 210 with Crohn's disease (CD) completed the survey, of which 82 (34%) and 97 (46%) patients, respectively, reported disease exacerbation within 2 months after the lockdown. The results suggest that changes in daily life and stress status due to the pandemic and lockdown measures were associated with worsening IBD symptoms, especially in young patients.

Global Crohn’s Disease Treatment Market: Key Developments

On June 17, 2022, AbbVie Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SKYRIZI (risankizumab-rzaa) as the first and only specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn's disease (CD).

In March 2022, Tiziana Life Sciences, a biotechnology company, had commenced a Phase Ib clinical trial of oral enteric-coated capsules of foralumab (TZLS-401), a monoclonal antibody (mAb), in mild-to-moderate Crohn’s disease (CD) patients.

Global Crohn’s Disease Treatment Market: Restraint

The major factors that hinder growth of the global crohn’s disease treatment market include low awareness about the available treatment options among people and high cost of the drugs used in the treatment of crohn’s disease. For instance, a 2019 study from the Crohn’s & Colitis Foundation found that people with Crohn’s disease typically incur about US$ 30,000 in care costs in the year of their initial diagnosis